Background: The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) is a fast, easy-to-administer and already widely validated neuropsychological battery for cognition in multiple sclerosis. Objective: The goals of our study were to validate the BICAMS in a Belgian Dutch-speaking population and to investigate to what extent including extensive versions of two of the three BICAMS subtests improved its psychometric qualities. Methods: Ninety-seven persons with MS and ninety-seven healthy controls were included and group-matched on age, education level and gender. All participants performed the BICAMS with an extensive version of the CVLT-II and BVMT-R. Results: The SDMT and BVMT-R were able to dissociate between the MS and healthy control group, while the CVLT-II was not. Distributions of CVLT-II scores suggest learning effects in the MS group, indicating the need for alternative word lists or the construction of an adapted version fitted for repeated administration. Including the full CVLT-II and BVMT-R did not markedly improve the psychometric qualities of the BICAMS. Conclusion: This study validates the BICAMS in a Belgian Dutch-speaking population and facilitates the use of it in clinical practice, while providing evidence that including full versions of the CVLT-II and BVMT-R does not increase its psychometric qualities markedly. ; MD has received travel grants, consultancy and speaker fees from Biogen, Teva, Novartis and Genzyme Sanofi. DL is a consultant for Novartis, Bayer, TEVA, Biogen and Merck, part of a speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer and Excemed and holds research grants from Novartis, Biogen and Bayer. All are paid into DL's university. GN holds a research chair by Merck and Novartis. None of these are likely to be relevant in the context of this manuscript.